Studies how the AMH hormone level relates to ovarian conditions and fertility
Observes anti-Müllerian hormone levels in women with PCOS, POI or fertility problems.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 22 Jun 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 27 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for girls and women who attend the named clinics for polycystic ovarian syndrome (PCOS) or premature ovarian insufficiency (POI), or who come for assisted reproductive technology (ART) treatment.
- Age
- From 10 to 44 years.
- Sex
- Female only.
Main reasons for not taking part
- Women younger than 10 or aged 45 or older
- Current or past diseases affecting gonadotropin or sex steroid secretion, clearance and excretion
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI
- Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment
Who cannot take part
- Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion
- Women with age <10 or ≥45
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 44 years old?
Where in Hong Kong
- The Chinese University of Hong KongHong Kong, Hong KongContact: PUI WAH JACQUELINE CHUNG, MBBSTaking people
About the trial
What the trial wants to find out
This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:
Read full original descriptionShow less
1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS. 2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI. 3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment. 4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment. 5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
- Plain-language title
- Studies how the AMH hormone level relates to ovarian conditions and fertilityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05858307, who can take part
- Record updated
- 27 March 2025